Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma

Redox Report

Volumn 21, Issue 5, 2016, Pages 204-208

  Faridvand, Yousef ^a   Oskuyi, Ali Eishi ^a   Khadem Ansari, Mohammad Hassan ^a  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

8 isoprostane; Multiple myeloma; Oxidative stress; Paraoxonase 1

Indexed keywords

8 ISOPROSTANE; ALBUMIN; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; BETA 2 MICROGLOBULIN; CALCIUM; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; 8-EPI-PROSTAGLANDIN F2ALPHA; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; PROSTAGLANDIN F2 ALPHA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CANCER STAGING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPECTROPHOTOMETRY; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

AGED; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; DINOPROST; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OXIDATIVE STRESS;

EID: 84978512265     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000215Y.0000000034     Document Type: Article

References (30)

1. B.Barlogie, J.Epstein. Multiple myeloma: biology and therapy. J Cancer Res Clin Oncol 1990;116(1):109–11. doi: 10.1007/BF01612651
2. N.Becker. Epidemiology of multiple myeloma. Recent Results Cancer Res 2011;183:25–35. doi: 10.1007/978-3-540-85772-3_2
3. I.Kuku, I.Aydogdu, N.Bayraktar, E.Kaya, O.Akyol, M.A.Erkurt. Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell Biochem Funct 2005;23(1):47–50. doi: 10.1002/cbf.1127
4. M.Gerber, C.Astre, C.Segala, M.Saintot, J.Scali, J.Simony-Lafontaine, Oxidant-antioxidant status alterations in cancer patients: relationship to tumor progression. J Nutr 1996;126(4):1201S–7S.
5. V.Sosa, T.Moline, R.Somoza, R.Paciucci, H.Kondoh, M.E.Lleonart. Oxidative stress and cancer: an overview. Ageing Res Rev 2012;12(1):37.90–6.
6. J.D.Morrow, K.E.Hill, R.F.Burk, T.M.Nammour, K.F.Badr, L.J.RobertsII,. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87(23):9383–7. doi: 10.1073/pnas.87.23.9383
7. G.Barrera. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012;2012:137289.
8. M.I.Mackness, B.Mackness, P.N.Durrington, P.W.Connelly, R.A.Hegele. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7(2):69–76. doi: 10.1097/00041433-199604000-00004
9. M.N.Akcay, I.Yilmaz, M.F.Polat, G.Akcay. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003;50(2):cclxxiii–cclxxv.
10. E.T.Elkiran, N.Mar, B.Aygen, F.Gursu, A.Karaoglu, S.Koca. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48. doi: 10.1186/1471-2407-7-48
11. M.Krzystek-Korpacka, D.Boehm, M.Matusiewicz, D.Diakowska, K.Grabowski, A.Gamian. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes – connection with inflammation. Clin Biochem 2008;41(10–11):804–11. doi: 10.1016/j.clinbiochem.2008.03.012
12. V.L.Stevens, C.Rodriguez, A.L.Pavluck, M.J.Thun, E.E.Calle. Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2006;15(6):1226–8. doi: 10.1158/1055-9965.EPI-05-0930
13. H.Balci, H.Genc, C.Papila, G.Can, B.Papila, H.Yanardag, Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J Clin Lab Anal 2012;26(3):155–60. doi: 10.1002/jcla.21503
14. J.Caers, E.Van Valckenborgh, E.Menu, B.Van Camp, K.Vanderkerken. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer 2008;95(3):301–13.
15. Y.J.Taverne, A.J.Bogers, D.J.Duncker, D.Merkus. Reactive oxygen species and the cardiovascular system. Oxid Med Cell Longev 2013;2013:862423. doi: 10.1155/2013/862423
16. S.Stojnev, A.Ristic-Petrovic, L.Jankovic-Velickovic. Reactive oxygen species, apoptosis and cancer. Vojnosanit Pregl 2013;70(7):675–8. doi: 10.2298/VSP1307675S
17. M.Martins Chaves, E.Rocha-Vieira, A.Pereira dos Reis, R.de Lima e Silva, N.C.Gerzstein, J.A.Nogueira-Machado. Increase of reactive oxygen (ROS) and nitrogen (RNS) species generated by phagocyting granulocytes related to age. Mech Ageing Dev 2000;119(1–2):1–8. doi: 10.1016/S0047-6374(00)00153-6
18. P.Montuschi, P.J.Barnes, L.J.Roberts2nd,. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18(15):1791–800. doi: 10.1096/fj.04-2330rev
19. M.H.Khadem-Ansari, Z.Shahsavari, Y.Rasmi, R.Mahmoodlo. Elevated levels of urinary 8-hydroxy-2′-deoxyguanosine and 8-isoprostane in esophageal squamous cell carcinoma. J Carcinog 2011;10:14. doi: 10.4103/1477-3163.79683
20. E.Dalaveris, T.Kerenidi, A.Katsabeki-Katsafli, T.Kiropoulos, K.Tanou, K.I.Gourgoulianis, VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer 2009;64(2):225–19. doi: 10.1016/j.lungcan.2008.08.015
21. T.Zima, I.Spicka, S.Stipek, J.Crkovska, J.Platenik, M.Merta, Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma. Neoplasma 1996;43(2):69–73.
22. A.Sharma, M.Tripathi, A.Satyam, L.Kumar. Study of antioxidant levels in patients with multiple myeloma. Leuk Lymph 2009;50(5):809–15. doi: 10.1080/10428190902802323
23. M.Lodh, B.Goswami, N.Gupta, S.K.Patra, A.Saxena. Assessment of oxidative stress and inflammatory process in patients of multiple myeloma. Indian J Clin Biochem 2012;27(4):410–3. doi: 10.1007/s12291-012-0222-y
24. S.Gangemi, A.Allegra, A.Alonci, M.Cristani, S.Russo, A.Speciale, Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res 2012;61(10):1063.7. doi: 10.1007/s00011-012-0498-7
25. H.Y.Ellidag, E.Eren, O.Aydin, M.Yildirim, C.Sezer, N.Yilmaz. Multiple myeloma: relationship to antioxidant esterases. Med Princ Pract 2014;23(1):18–23. doi: 10.1159/000355826
26. A.Sehitogullari, M.Aslan, F.Sayir, A.Kahraman, H.Demir. Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma. Redox Rep 2014;19(5):199–205. doi: 10.1179/1351000214Y.0000000091
27. M.N.Akcay, M.F.Polat, I.Yilmaz, G.Akcay. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003;50(2):ccxxv–ii.
28. K.Siemianowicz, J.Gminski, M.Stajszczyk, W.Wojakowski, M.Goss, M.Machalski, Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med 2000;6(3):307–11.
29. M.von Meyenfeldt. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 2005;9(2):S35–8. doi: 10.1016/j.ejon.2005.09.001
30. J.R.Jackson, M.P.Seed, C.H.Kircher, D.A.Willoughby, J.D.Winkler. The codependence of angiogenesis and chronic inflammation. FASEB J 1997;11(6):457–65.